Thinking about what to do with Eli Lilly shares? You’re certainly not alone. The stock has been climbing the leaderboard for ...
Lilly predicts it will achieve an adjusted profit of between $23.00 and $23.70 per share this year, an increase on its ...
October 30th is the day when Eli Lilly will report its third-quarter results, including sales of its 'superstars' Zepbound ...
Get the latest on Novo Nordisk's Alzheimer's trial, stock outlook, and market risks. See what investors need to know before ...
A new blood test that could help doctors identify whether a patient has Alzheimer’s disease was cleared by the FDA last week.
Eli Lilly (NYSE: LLY) has been one of the best-performing healthcare giants over the past decade. It now stands as the largest in the sector by market cap. Even with headwinds it has encountered this ...
Independent.ie on MSN
Eli Lilly tells Government it has concerns over proposed EU law changes
The US pharmaceutical company Eli Lilly has met with the Department of Enterprise to express concerns about planned changes to the patent law in Europe. The multinational, which employs 3,500 people ...
The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2025 of $1.50 ...
Oct 6 (Reuters) - Eli Lilly (LLY.N), opens new tab will invest more than $1 billion in India in the coming years to boost manufacturing and supply through local drugmakers, the company said on Monday, ...
Medical Device Network on MSN
FDA clears Roche’s blood-based test for Alzheimer’s assessment
The US FDA has granted clearance for Roche's Elecsys pTau181 test for the preliminary evaluation of Alzheimer's disease.
The test—developed in collaboration with Eli Lilly and Co.—does not diagnose Alzheimer’s but is designed to rule out the ...
Labcorp plans to offer Roche’s recently FDA-cleared blood test to assess early signs of Alzheimer’s disease and other causes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback